Medina Manuel Hidalgo Sells 1,000 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,000 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $130.06, for a total value of $130,060.00. Following the transaction, the director owned 639 shares in the company, valued at approximately $83,108.34. This represents a 61.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Wednesday, May 20th, Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock. The stock was sold at an average price of $107.09, for a total value of $133,862.50.
• On Friday, March 6th, Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock. The stock was sold at an average price of $91.54, for a total value of $119,002.00.

Guardant Health Trading Down 2.6%

Shares of GH stock traded down $3.53 during midday trading on Friday, reaching $129.69. 3,513,756 shares of the stock were exchanged, compared to its average volume of 2,126,946. Guardant Health, Inc. has a 1 year low of $38.03 and a 1 year high of $133.97. The company’s 50 day moving average is $94.23 and its two-hundred day moving average is $99.73. The firm has a market cap of $17.20 billion, a PE ratio of -38.26 and a beta of 1.48.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Guggenheim downgraded Guardant Health from a “buy” rating to a “buy” rating in a report on Thursday. Stifel Nicolaus upped their target price on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Leerink Partners upped their target price on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, February 20th. Evercore set a $110.00 target price on Guardant Health in a report on Friday, February 20th. Finally, Barclays upped their price target on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.79.

Institutional Trading of Guardant Health

Several hedge funds and other institutional investors have recently made changes to their positions in GH. Alyeska Investment Group L.P. purchased a new stake in shares of Guardant Health in the 3rd quarter worth approximately $114,421,000. Price T Rowe Associates Inc. MD lifted its position in Guardant Health by 33.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after acquiring an additional 1,414,441 shares in the last quarter. Norges Bank bought a new position in Guardant Health in the 4th quarter valued at approximately $128,499,000. Summit Partners Public Asset Management LLC lifted its position in Guardant Health by 674.5% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company’s stock valued at $87,019,000 after acquiring an additional 741,958 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in Guardant Health by 26.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock valued at $182,836,000 after acquiring an additional 606,368 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.